Skip to content
10-Q

Quarterly Report

KALARIS THERAPEUTICS, INC. KLRS

0001193125-26-219328

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 23.79M sh
Shares Diluted Q1 2026 · Mar 31, 2026 23.72M sh
Shares Diluted Q1 2026 · Mar 31, 2025 4.05M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$11.58M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$7.44M
Short Term Investments Q1 2026 · Mar 31, 2026 $62.79M
Short Term Investments Q1 2026 · Dec 31, 2025 $19.93M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $34.43M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $98.05M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $100.97M
Stockholders Equity Q1 2026 · Mar 31, 2026 $68.56M
Stockholders Equity Q1 2026 · Dec 31, 2025 $78.81M
Stockholders Equity Q1 2026 · Mar 31, 2025 $63.87M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$96.62M
Current Liabilities Q1 2026 · Mar 31, 2026 $8.08M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.71M
Total Liabilities Q1 2026 · Mar 31, 2026 $41.25M
Total Liabilities Q1 2026 · Dec 31, 2025 $42.92M
Current Assets Q1 2026 · Mar 31, 2026 $98.47M
Current Assets Q1 2026 · Dec 31, 2025 $118.81M
Total Assets Q1 2026 · Mar 31, 2026 $109.81M
Total Assets Q1 2026 · Dec 31, 2025 $121.74M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.46
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.52
Eps Basic Q1 2026 · Mar 31, 2026 −$0.46
Eps Basic Q1 2026 · Mar 31, 2025 −$2.52
Sga Expense Q1 2026 · Mar 31, 2026 $4.26M
Sga Expense Q1 2026 · Mar 31, 2025 $4.32M
Rd Expense Q1 2026 · Mar 31, 2026 $7.57M
Rd Expense Q1 2026 · Mar 31, 2025 $6.03M
Net Income Q1 2026 · Mar 31, 2026 −$10.86M
Net Income Q1 2026 · Mar 31, 2025 −$10.2M
Operating Income Q1 2026 · Mar 31, 2026 −$11.83M
Operating Income Q1 2026 · Mar 31, 2025 −$10.35M